Advanced Medicine
Clinical and translational frontiers: immunotherapy, mRNA and gene editing, gene and cell therapy, incretin drugs, neurodegeneration, aging, infectious disease, cardiovascular therapeutics and clinical AI.
Cancer Immunotherapy
Immune checkpoint inhibitors, CAR-T and TIL cell therapies including solid tumors, T-cell engagers and bispecifics, and antibody-drug conjugates.
mRNA Therapeutics & Cancer Vaccines
Personalized neoantigen mRNA vaccines, lipid-nanoparticle delivery, self-amplifying and circular RNA and mRNA therapeutics beyond infectious disease.
CRISPR & Gene-Editing Therapies
Approved and investigational CRISPR-Cas9 therapies, base and prime editing, in vivo LNP-delivered editing and bespoke editing for ultra-rare disease.
Gene & Cell Therapy
AAV and lentiviral gene therapy, in vivo CAR-T, iPSC- and stem-cell-derived replacement therapies such as islets and dopaminergic neurons.
GLP-1 & Incretin Therapies
Semaglutide, tirzepatide and next-generation incretin agonists; obesity, diabetes, cardiovascular, renal, liver and neuropsychiatric outcomes.
Alzheimer's, Parkinson's & Neurodegeneration
Anti-amyloid antibodies, plasma p-tau biomarkers, alpha-synuclein seed amplification, antisense therapies for ALS and emerging disease-modifying strategies.
Biology of Aging & Longevity
Hallmarks of aging, senolytics, epigenetic clocks, partial reprogramming, mTOR and other geroprotective interventions.
Infectious Disease, Vaccines & Antimicrobial Resistance
New antibiotic classes and AI-discovered antibiotics, phage therapy, long-acting HIV prevention and next-generation vaccines.
AI in Clinical Medicine
Validated diagnostic AI, medical large language models, AI-discovered drug candidates in clinical trials and evidence standards for clinical deployment.
Cardiovascular Therapeutics
Lipoprotein(a)-lowering drugs, siRNA and gene-editing approaches to LDL cholesterol, CETP inhibition and other cardiovascular advances.